Global EditionASIA 中文雙語Fran?ais
    Business
    Home / Business / Companies

    Sinopharm unit inches toward vaccine breakthrough

    By Liu Zhihua | China Daily | Updated: 2020-04-30 10:42
    Share
    Share - WeChat
    A China National Biotech Group Co Ltd employee displays a COVID-19 inactive vaccine, which is under development and trials, at the company's research institute in Wuhan, capital of Hubei province, on April 10. [Photo/Xinhua]

    State-owned CNBG teams up with partners to step up development of effective, lasting treatment for COVID-19

    Chinese State-owned pharmaceutical giant Sinopharm Group has made substantial progress in developing vaccine candidates for the novel coronavirus that causes COVID-19.

    China National Biotech Group Co Ltd, Sinopharm's vaccine and bioscience unit, announced on Monday that its second inactivated vaccine targeting the contagion won clinical trial approval from the National Medical Products Administration. The vaccine is codeveloped by a unit under CNBG-Beijing Institute of Biological Products Co Ltd-and the Chinese Center for Disease Control and Prevention.

    On Friday, CNBG launched phase-2 human trials of its first inactivated vaccine, which is codeveloped by its unit, the Wuhan Institute of Biological Products, along with the Wuhan Institute of Virology under the Chinese Academy of Sciences.

    Approved for clinical trials on April 12, the vaccine was the first inactivated vaccine worldwide to reach such a developed approval stage. The NMPA authorized its phase-1 and phase-2 human trials at the same time on that day through a fast-track channel based on solid results from preclinical trial studies.

    "The world is racing to develop COVID-19 vaccines, yet it is not a competition between countries, but rather a race between humans and the virus," said Yang Xiaoming, president of CNBG.

    Yang said it is quite encouraging to have developed inactivated vaccines against COVID-19.

    Inactivated vaccines use nonliving viruses, bacteria or other pathogens that have lost disease-producing capacity to stimulate the immune system to develop an immune response.

    Wang Junzhi, an academic at the Chinese Academy of Engineering, said China has laid a solid foundation to research inactivated vaccines in recent years, and inactivated vaccines have been widely used to fight hepatitis A, influenza, poliomyelitis, and hand, foot and mouth disease.

    Yang added that China has distinctive advantages in developing vaccines against the disease thanks to the country's institutional features that can unite resources and efforts of different participants to concentrate on a specific program and target.

    1 2 3 Next   >>|
    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    CLOSE
     
    无码国产精品一区二区免费式影视| 人妻丰满熟妞av无码区| 丰满熟妇人妻Av无码区| 精品无码国产一区二区三区AV| 人看的www视频中文字幕| 四虎成人精品无码| 久久AV高潮AV无码AV| 久久精品中文字幕久久| 内射无码午夜多人| 国产午夜精品无码| 无码中文字幕乱在线观看| 中文字幕九七精品乱码| 国产精品中文字幕在线观看| 中文无码一区二区不卡αv| 国产精品va在线观看无码| 人妻少妇乱子伦无码视频专区| 亚洲精品无码久久久久| 国产成人无码免费看视频软件| 中文www新版资源在线| 中文毛片无遮挡高潮免费| 四虎成人精品国产永久免费无码| 国产免费无码一区二区| 久久精品aⅴ无码中文字字幕不卡| 亚洲精品无码久久千人斩| 亚洲国产一二三精品无码| 中文字幕乱人伦| 欧美日韩毛片熟妇有码无码| 中文字幕日韩理论在线| 成人麻豆日韩在无码视频| 中文字幕一区二区三区日韩精品| 亚洲欧美日韩在线不卡中文| 大蕉久久伊人中文字幕| 亚洲av午夜国产精品无码中文字| 婷婷综合久久中文字幕| 中文字幕日韩一区二区三区不卡| 色综合久久中文色婷婷| 久久伊人中文无码| 极品粉嫩嫩模大尺度无码视频| 亚洲真人无码永久在线| 无码人妻精品一区二区三区在线 | 亚洲AV无码一区二三区|